Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Optimi Health Corp C.OPTI

Alternate Symbol(s):  OPTHF

Optimi Health Corp. is an end-to-end drug researcher and formulator licensed by Health Canada to produce and supply, for clinical research purposes, psychedelic substances, such as 3,4-Methylenedioxymethamphetamine (MDMA), natural Manufacturing Practices (GMP)-grade psilocybin, as well as functional mushrooms that focus on the health and wellness markets. The Company produces scalable... see more

Recent & Breaking News (CSE:OPTI)

Optimi Health Achieves Milestone: Completes In-House Production of MDMA Active Pharmaceutical Ingredient (API)

GlobeNewswire 1 day ago

Optimi Health Signs Psilocybin Supply Agreement With New Zealand-Based Mātai Medical Research Institute

GlobeNewswire 7 days ago

Optimi Health Receives Finished Product Test Results and Certificate Of Analysis for GMP Natural Psilocybin Extract

GlobeNewswire April 2, 2024

Optimi Health Confirms Presenting Sponsorship at the 4th Annual Psychedelic Therapeutics and Drug Development Conference

GlobeNewswire March 28, 2024

Optimi Health to Supply MDMA for Psychedelic Research at Tel Aviv University

GlobeNewswire March 26, 2024

Optimi Announces Closing of First Tranche of Non-Brokered Private Placement

GlobeNewswire February 28, 2024

Optimi Health Congratulates Lykos Therapeutics on FDA Priority Review of New Drug Application And Releases MDMA Production Video

GlobeNewswire February 12, 2024

Optimi Announces Non-Brokered Private Placement

GlobeNewswire February 8, 2024

Optimi Health To Host MDMA Educational Quality Assurance Webinar For Clinicians And Practitioners

GlobeNewswire February 6, 2024

Optimi Health increases MDMA quantities, bets on FDA approval

Jonathon Brown January 19, 2024

Optimi Health Secures Amendment to Increase Quantities Of MDMA, MDA, And 2C-B Under Controlled Drugs And Substances Dealer's Licence

GlobeNewswire January 19, 2024

Optimi Health Granted Precursor Licence To Formulate MDMA And Completes Encapsulation Of 40mg And 60mg Dosage Formats

GlobeNewswire January 3, 2024

Optimi Health and Sunshine Earth Labs Ltd. Forge Strategic Supply Agreement

GlobeNewswire December 7, 2023

Optimi Health completes psilocybin extract validation

Jonathon Brown November 28, 2023

Optimi Health Achieves Genetics Milestone and Completes Psilocybin Extract Validation and Stability Testing

GlobeNewswire November 28, 2023

Optimi Health Resolves Dispute

GlobeNewswire November 10, 2023

Optimi Health Welcomes Dr. Preston A. Chase as New Chief Science Officer

GlobeNewswire November 7, 2023

Optimi Health Announces Third and Final Tranche of CAD $1,000,000 Secured for Debt Financing

GlobeNewswire November 2, 2023

Optimi Health Celebrates Encouraging Results from the MAPS Phase 3 MDMA-Assisted Therapy Clinical Trial

GlobeNewswire September 14, 2023

Optimi Health Granted Amendment to Dealer's Licence by Health Canada to Supply Special Access Program

GlobeNewswire September 7, 2023